Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer (Breast Cancer Research (2020) 22: 4 DOI: 10.1186/s13058-019-1243-8)

Lori J. Goldstein, Raymond P. Perez, Denise Yardley, Linda K. Han, James M. Reuben, Hui Gao, Susan McCanna, Beth Butler, Pier Adelchi Ruffini, Yi Liu, Roberto R. Rosato, Jenny C. Chang

Research output: Contribution to journalArticle

Abstract

After publication of the original article [1], the authors identified two errors in the Author details: 1. Sarah Cannon Research Institute, Nashville, TN, should be added to Dr. Yardley's affiliation in addition to Tennessee Oncology. 2. Dr. Yardley has provided services to multiple companies on behalf of Sarah Cannon Research Institute.

Original languageEnglish (US)
Article number52
JournalBreast Cancer Research
Volume22
Issue number1
DOIs
StatePublished - May 20 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer (Breast Cancer Research (2020) 22: 4 DOI: 10.1186/s13058-019-1243-8)'. Together they form a unique fingerprint.

  • Cite this